.Pharmacolibrary.Drugs.ATC.J.J05AP51 .Pharmacolibrary.Drugs.ATC.J.J05AP51| name: | SofosbuvirAndLedipasvir | |
| ATC code: | J05AP51 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 47 | L |
| clearance: | 13 | L/h |
| other parameters in model implementation | ||
Sofosbuvir and ledipasvir is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, and ledipasvir is an inhibitor of the HCV NS5A protein. This combination is approved for use in adults and children above 3 years for several HCV genotypes.
Pharmacokinetic parameters reported for healthy adult volunteers after administration of a single fixed-dose oral tablet containing ledipasvir 90 mg and sofosbuvir 400 mg (as Harvoni).